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Tele-ophthalmology in the Community Pharmacy Setting:
A Novel Model of Care
Diabetic retinopathy (DR) is a retinal vascular
disorder characterized by changes in the blood
vessels of the retina that begins without symptoms
and can advance to blurry vision, dark or floating
spots, difficulty differentiating colors, and/
or problems focusing.1,2 Blindness and vision
impairment in adults due to DR are highly prevalent
and disabling conditions in the US, affecting at least
3.3 million people over age 65.2-6 The number of
people with DR will increase more than three-fold
by 2050, creating an immense and costly public
health problem.7-9 In 2004, for example, blindness
from DR accounted for approximately $500
million in direct medical costs, and exponentially
more in indirect costs to society.10 Clinical trials
demonstrating the efficacy of these treatments led
the American Academy of Ophthalmology and the
American Diabetes Association to recommend
that all patients with diabetes have annual dilated
fundus examinations (DFEs) to reduce their risk
of vision loss.11,12 In addition, Healthy People 2010
goals encourage 75% of all persons with diabetes
to have a DFE.13 New effective treatment can also
slow the rate of progression of retinopathy1. Despite
this fact, only 50% to 60% of adults with diabetes
follow this recommendation and an estimated 50%
of patients are diagnosed too late for treatment to
be effective. 13-15
The Wills Eye Institute Department of Research
is participating in a collaborative study with the
Centers for Disease Control and Prevention along
with other leading U.S. eye care institutions. One of
the initiatives being tested is the use of a non-dilated
eye screening program for people with diabetes, in
a pharmacy-based setting. These screenings have
the potential to improve health care outcomes and
compliance by increasing access to eye care and
earlier detection of diabetic retinopathy.

Eye screenings are taking place at the outpatient
pharmacy operated by the Thomas Jefferson
University Hospital in Philadelphia. Before patients
are screened, they complete a brief questionnaire
to capture the patient’s past medical history,
hemoglobin A1c levels, and current diabetes
medications. The screening process takes less than
ten minutes and consists of a visual acuity test,
followed by a fundus photo (painless, non-dilated
image of the retina taken with a Nidek camera).
The images are sent electronically to the Wills Eye
Department of Telemedicine and read by retina
specialists. The final diagnosis and follow-up
recommendations are mailed to the patient within
two weeks. This technology has the potential to
facilitate access to eye care for patients with diabetes,
and to delay the progression to diabetic retinopathy.
Furthermore, when located in a community
pharmacy setting, this screening is very convenient
for patients who are short on time or do not have the
financial resources or health insurance to cover visits
to a specialist. Since this eye screening does not
require dilation of the pupils, minimal time is spent
getting an eye exam.
While tele-opthalmology screenings hold promise
for improving patient care, the utility of this
technology in community settings depends on
the volume of patients screened. The current
study is being conducted in a pharmacy with an
average of 1700 prescriptions filled weekly. Longterm sustainability will depend on 1) whether
or not insurance companies will add it to health
care coverage, and 2) whether participating
pharmacists are afforded the necessary time to
contribute. To date, Wills Eye has screened a total
of 143 patients; preliminary findings suggest that
more than 10% of patients show signs of diabetic
retinopathy (background diabetic retinopathy,

proliferative diabetic retinopathy, pre-proliferative
diabetic retinopathy, maculopathy or previous laser
treatment). Early data also suggest that the camera
has the potential to detect other eye abnormalities
such as cataracts and hypertensive changes. These
results provide incentive and purpose for future
utilization of tele-opthalmology screenings.
The program represents a novel model for
engaging community pharmacists in a team
approach to managing diabetes. Pharmacists
are considered to be trusted health professionals
and are generally very accessible. Specific actions
taken by pharmacists involved in the program
include: counseling patients on the importance
of eye screening when they pick up their diabetes
medications and providing continued reminders
to the patient about the importance of following up
with their physician about diabetes eye care.
Data on the impact of the program, number
of patients with DR, and outcomes are being
collected. Primary measures include the impact
of the screening in detecting DR and the rate of
patient follow-up to an ophthalmologist for ocular
pathology detection at the screening. If successful,
the program has the potential to stimulate adoption
of this emerging technology in other community
pharmacy settings. 
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